Introduction
Myelodysplastic syndromes (MDS) are clonal stem cell disorders predominantly of the elderly, characterised by ineffective haematopoiesis, peripheral cytopenias and progressive loss of myeloid differentiation, causing substantial morbidity and mortality. 1 Although the initiating events occur at the genetic level of haematopoietic stem cells, haematopoietic failure in the early stage of the disease results, at least partly, from alterations of the immune system. Intramedullary (paracrine) secretion of proapoptotic cytokines, such as tumor necrosis factor a, transforming growth factor b, interleukin 1b and interferon g, has been shown to inhibit haematopoietic precursors and contribute to excessive apoptosis in MDS. [2] [3] [4] T cells from MDS patients may suppress erythroid and granulocytic colony growth in vitro, 5, 6 as in aplastic anaemia. Indeed, results of immunosuppressive therapy in aplastic anaemia 7, 8 have motivated the use of horse or rabbit ATG 9 in single cases and in a small series of (mostly hypoplastic) MDS as early as 1988. [10] [11] [12] [13] [14] In 1997, Molldrem et al 15 reported that up to 64% of patients with refractory anaemia (RA) responded to rabbit ATG treatment, with an overall response rate of 44% in MDS patients, later corrected to 34% in the last follow-up of 61 patients. 16 The treatment of MDS with other immune-modulating drugs such as cyclosporine (CsA) 17 has also yielded encouraging results, but the apparent need for continuous CsA therapy constitutes a serious drawback for this approach.
We conducted an open-labelled, prospective, randomised, phase II study of horse ATG vs rabbit ATG in patients with lowrisk MDS with the intention to verify the reported response rates with regard to the improvement of haematopoietic insufficiency and to evaluate the respective efficacy and safety of both antiserum preparations as a basis for future phase III trials.
Materials and methods

Study design
In October 1998, we initiated an open-labelled, prospective, randomised, multicentre, phase II study to evaluate the efficacy and safety of horse ATG vs rabbit ATG in patients with low-risk MDSs. Primary end points were rate and duration of response; secondary end points were side effects and progression of disease. The study was conducted in complete concordance with the declaration of Helsinki and approved by the ethics committees of the participating institutions. The inclusion criteria were: patients with the following cytologically and/or histologically proven MDS of FAB subtypes: 18 RA, RA with excess blasts (RAEB) or chronic myelomonocytic leukaemia (CMML); clinically significant cytopenias (haemoglobin o10 g/ dl or platelets o50 000/ml or neutrophils o1000/ml); ECOG performance status 0-2; age 418 years; and written informed consent. The exclusion criteria were: FAB subtype RA with ringed sideroblasts, as none of such patients had shown any response to rabbit ATG in a previous study; 15 FAB subtype RAEB in transformation (RAEB-T), since such patients should receive cytoreductive therapy; MDS patients with an available donor and scheduled for allogeneic stem cell transplantation; other MDS-specific therapies (apart from transfusions and supportive care) less than 4 weeks prior to study therapy; prior therapy with and sensitisation against horse ATG or rabbit ATG; serious coexisting diseases (especially uncontrolled malignancies or HIV infection) or special conditions of health (eg pregnancy and lactation); and other study medications.
Treatment protocol
Prior to registration in the study, central morphology evaluation was required for all patients (performed by CA for bone marrow cytology and by HHK for bone marrow histology) to ensure maximum concordance on diagnosis and stage. Cytology samples were later re-evaluated in a blinded fashion by an independent reviewer (HH s is approved both in Europe and the US. In both arms of the study, patients received methylprednisolone to prevent or alleviate allergic reactions and serum sickness: 5 mg/kg of body weight/day intravenously during the first 5 days, 30 min prior to horse ATG or rabbit ATG (with a potential increase to 10 mg/kg of body weight/day at the responsible physician's discretion in cases of vigorous allergic reaction), thereafter 1 mg/kg of body weight/ day orally until day 14, at which point the dose was then gradually reduced to be discontinued on day 28. Supportive care (antimicrobial prophylaxis and therapy in neutropenic patients, red cell, platelet and plasma transfusions, etc) was also standardised, as were bone marrow and laboratory evaluations before and at specified time points after study therapy. The response criteria were essentially those used by Molldrem et al, 15 modified according to Hellströ m-Lindberg et al: 19 complete normalisation of haemoglobin (412 g/dl), platelet (4100 000/ ml) and neutrophil counts (41500/ml) was required for complete response (CR); transfusion independence for red cells or platelets or clinically significant rises in blood counts (increase in haemoglobin by more than 2 g/dl or platelets above 100 000/ ml or neutrophils above 1500/ml) were classified as good response (GR); moderate improvements to maintain stable blood counts (haemoglobin 48 g/dl and platelets 420 000/ml and neutrophils 4500/ml) were considered minor response (MR).
Statistical analysis
Overall survival was considered as the time from the date of the first horse ATG or rabbit ATG administration until death from any cause or date of last evaluation. Survival curves were drawn according to Kaplan and Meier 20 and differences were estimated by the log-rank test.
Statistical evaluation of possible predictive parameters for response was performed by univariate analysis using Fisher's exact probability test for each of the following covariates: age, sex, positivity for HLA DRB1n15, 21 bone marrow cellularity, classification according to FAB and WHO, 22 IPSS score, 23 cytogenetics, number of cytopenias, prior specific MDS therapy, randomisation into the horse ATG or rabbit ATG group or side effects.
Multivariate analysis on the statistically significant covariates was performed by backward stepwise logistic regression using the log-rank test.
Results
Patients' characteristics
Of the 38 patients enrolled into the study, three were not evaluable because of early progression to RAEB-T or secondary AML after randomisation, prior to the initiation of study therapy. Primary data on all 35 evaluable patients are presented in Table 1 . Table 2 shows that the baseline characteristics are distributed equally with no significant differences between both arms. In all, 13 patients (37%) had previously been treated with hormones, vitamins, cytokines, chemotherapy, amifostine, CsA or thalidomide. Relevant comorbidity was present in 25 patients (71%), including cardiac, vascular, metabolic, chronic infectious or inflammatory diseases. Three patients had previously been treated for malignancies.
Side effects of study medication
Owing to single patient accrual in some institutions, 20 patients received horse ATG, while 15 were treated with rabbit ATG. Study therapy was completed in 30 of 35 patients with 10075% of doses administered. In one patient, rabbit ATG had to be stopped after 3 days (corresponding to 60% of the intended dose) due to a severe acute psychotic episode, most likely associated with the steroid medication. In four patients, steroid dose had to be increased because of vigorous allergic reactions. Whereas 12 patients tolerated study therapy well without complications, 23 developed adverse effects 41II WHO (the degree of toxicity encountered according to the internationally accepted WHO toxicity grading), mostly serum sickness (13 patients). Four serious adverse events occurred: pulmonary embolism, paralytic ileus and acute psychosis, which resolved with conservative management in three patients. The fourth patient died from rhinocerebral mucormycosis 2 weeks after rabbit ATG therapy. The frequency and severity of side effects were distributed equally between both treatment arms.
Response to study medication
Responses to the study drugs (Table 3) were observed in 12 out of 35 patients (34%): four CRs, six GRs and two MRs. While all CRs and GRs occurred in patients with RA, MRs were achieved in one patient with RAEB and one with CMML. Time to response varied between 1 and 10 (median: 3) months in all three cell lineages (Figures 1-3 ). Responses had a median duration of 9 (range: 1-17 þ ) months. In January 2002, five out of 12 patients were in continuing response. CRs and GRs were equally 
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distributed between RA patients in both treatment arms with five responders out of 12 (42%), each; the two MRs occurred in the horse ATG group. In six responders a normal karyotype had been found initially, while the other six had shown karyotypic abnormalities. Follow-up cytogenetics were available in three out of six patients in either group: no cytogenetic normalisation was observed after immunosuppressive treatment in the three responders with initial aberrant karyotype and follow-up cytogenetics available.
Long-term outcome
None of the patients reaching CR or GR progressed to more advanced MDS or AML. Both MR patients had an initial reduction in bone marrow blasts and showed prolonged survival even after progressing to secondary AML 10 and 20 months later, respectively. Among the 22 surviving nonresponders, 14 remained stable throughout follow-up, five showed early progression (within 6 months) and three late progression (beyond 6 months). Overall, at last follow-up, 24 patients were alive with an actuarial survival of 69% after 1 to 34 (mean: 15) months; three of 11 deaths were due to causes unrelated to MDS. There was no difference in overall survival between patients treated with horse ATG or rabbit ATG (Figure 4) . 1II ¼ the degree of toxicity encountered. 
Responders
Figure 3
Changes in neutrophil counts of representative patients responding to horse ATG or rabbit ATG.
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Factors predictive for response
Several parameters were analysed as possible predictive factors for response to immune-modulating therapy with horse ATG or rabbit ATG (Table 4) . By Fisher's exact probability test in univariate analysis, response to study therapy was significantly associated with classification according to FAB or WHO criteria, and with the interval from diagnosis to study therapy. The latter was the single most important factor for survival in multivariate analysis. There was no statistically significant association between response to study therapy and age, sex, positivity for HLA DRB1n15, bone marrow cellularity, cytogenetics, number of cytopenias, prior specific MDS therapy, randomisation into the horse ATG or rabbit ATG group or side effects. Patients with lower IPSS score tended to have more favourable outcomes; however, this tendency was not statistically significant.
Discussion
In this open-labelled, prospective, randomised, multicentre study of horse ATG vs rabbit ATG, both antisera preparations could be safely administered with adverse effects well known from trials with these agents in aplastic anaemia. 7, 8 We confirmed a response to immune-modulating treatment with both antiserum preparations in about one-third of patients with low-risk MDS. Responses most often occurred with latency as seen in patients with aplastic anaemia, 7, 8 and frequently lasted for a prolonged period, that is, were significant for the responding patient, suggesting that mechanisms leading to haematopoietic insufficiency may be similar in early-stage MDS and aplastic anaemia. Indeed, in patients with MDS T-lymphocyte clonal dominance has been demonstrated with a regression of dominant clones in patients responsive to immunosuppression. 24 Clinically relevant responses (CRs and GRs) were achieved with either horse ATG or rabbit ATG in 42% of RA patients. Since there was no significant difference between the two treatment arms with regard to clinically relevant responses, overall survival or adverse effects, this study does not support using either of the antiserum preparations over the other. Similar to a previous trial, 16 these responses were restricted to patients with favourable features, as indicated by low FAB or WHO stage, IPSS score, and start of treatment within 6 months after diagnosis of MDS. In addition, molecular analyses in a subgroup of female patients in this trial identified the presence of a 'nonclonal' pattern of X-chromosome inactivation in bone marrow cells as a predictor for favourable response to horse or rabbit ATG. 25 Compared to a previous single-arm study of rabbit ATG, 16 considerably fewer of our patients had favourable characteristics, for example, normal karyotype (42 vs 54%) or hypoplastic bone marrow (11 vs 38%). On the other hand, fewer of our patients had been treated previously (37 vs 74%). In addition, we started immunotherapy earlier after initial diagnosis (median: 11 vs 18.5 months). Another single-arm study of horse ATG 26 yielded comparable response rates (10 out of 20 evaluable patients, however, after exclusion of two severe adverse event (SAE) patients). Horse ATG, as a rescue approach in nonresponders to CsA, has been reported to be effective in one out of three patients with RA. 27 HLA-DRB1 status was not a significant prognostic factor in our cohort, unlike in the highly selected hypocellular patients reported from the NIH; 21 however, HLA-DRB1 typing was available only in a minority of patients. The higher age range of our patients, with a median of 63 years and no patient younger than 41 years, may explain why we were unable to confirm Kaplan-Meier estimate of overall survival of patients after treatment with either horse ATG or rabbit ATG. Table 4 Predictive factors for CR or GR to horse ATG or rabbit ATG Favourable group (responding/total) Unfavourable group (responding/total) Significant correlation in univariate analysis (Po0.05) younger age as a prognostic factor for response to ATG. Using univariate analysis, response was significantly associated with classification according to the FAB subtype RA, the WHO subtypes RA or refractory cytopenia with multilineage dysplasia, and a short interval from diagnosis to treatment with either horse ATG or rabbit ATG. As in support of our identification of prognostic factors for response to ATG, failure of rabbit ATG was recently reported in a small series of eight unselected MDS patients: 28 six had RAEB and five, including the two patients with RA, had not been treated within half a year after diagnosis of MDS.
In conclusion, both horse ATG and rabbit ATG were comparably safe and effective as palliative treatment for patients with low-risk MDS, improving sequelae of bone marrow failure in 42% of patients with RA. A randomised, phase III study is currently underway to determine the clinical benefit of combined immune modulatory treatment with ATG and CsA in patients with low-risk MDS.
